Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05702398 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Trial of Supplemental Vitamin A and Nicotinamide
A Early Phase 1 study of Skin Cancer and Kidney Transplant Recipients, sponsored by Rhode Island Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05702398: Recruiting Early Phase 1 study of Skin Cancer and Kidney Transplant Recipients, sponsored by Rhode Island Hospital.
NCT05702398 is a Early Phase 1 study of Skin Cancer and Kidney Transplant Recipients that is actively recruiting participants, run by Rhode Island Hospital. The registered enrollment target is 30 participants, below the 463-participant average among 40 other Skin Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05702398, a Early Phase 1 study of Skin Cancer and Kidney Transplant Recipients, is actively recruiting participants, sponsored by Rhode Island Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.
Conditions Studied
Interventions
- DRUG Nicotinamide
- DRUG Vitamin A
- OTHER Other: Placebo
Study Locations (1)
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2028-03-01 |
| Phase | Early Phase 1 |
What NCT05702398 shows while recruiting
NCT05702398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 463-participant average among 40 other Skin Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Skin Cancer appearing as the primary indexed condition, and to 3 interventions - of which Nicotinamide is the first listed.
NCT05702398 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT05702398 about?
NCT05702398 is a clinical study titled "Pilot Trial of Supplemental Vitamin A and Nicotinamide". The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention cl...
What is the current status of trial NCT05702398?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-04-01. Estimated completion is 2028-03-01.
What conditions does trial NCT05702398 study?
This clinical trial studies the following conditions: Skin Cancer, Kidney Transplant Recipients.
What interventions are being tested in trial NCT05702398?
The interventions under investigation include: Nicotinamide (DRUG), Vitamin A (DRUG), Other: Placebo (OTHER).
Who is sponsoring clinical trial NCT05702398?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05702398 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05702398's enrollment target sits among peer trials
30 31st of 40 higher than 9 of 40 other Skin Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
RECRUITING · Early Phase 1
-
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
RECRUITING
-
Undergraduate Skin Cancer Prevention Trial
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI